Medical Terms Learned today

In the according-to-protocol analyses, the rate of vaccine efficacy against incident infection with HPV-16 and HPV-18 was 91.6% (95% confidence interval [CI], 64.5 to 98.0) and the rate of efficacy against persistent infection was 100% (95% CI, 47.0 to 100). In the intent-to-treat analyses, the rate of vaccine efficacy against persistent cervical infection with HPV-16 and HPV-18 was 95.1% (95% CI, 63.5 to 99.3) and the rate of efficacy against cytologic abnormalities associated with HPV-16 and HPV-18 infection was 92.9% (95% CI, 70.0 to 98.3). The vaccine was generally safe, well tolerated, and highly immunogenic.
Lancet. 2004;364:1757-1765